Merus N.V. (MRUS)

Analysts 3
Positive
33%
Median target $31 (47% upside)


    • 01/02/18
      RBC Capital
      sector perform
    • 07/17/17
      Jefferies
      buy
      $31
    • 03/21/17
      Citigroup
      neutral
      $31
      "The market has rightfully awarded MRUS credit for the Incyte deal and the stock is up ~50% since..."
      View details
    • 12/21/16
      Wedbush
      outperform
      $32
      "We believe the collaboration [with Incyte to develop up to eleven bispecific antibody research..."
      View details
    • 06/13/16
      Guggenheim
      buy
      $18
    • 33% positive
      $31 Median

    Best rated stocks last 7 days

    more

    Most rated stocks last 72 hrs

    more